Resverlogix Corp. announced that it is in active discussions with the Kingdom of Morocco?s Ministry of Health for possible Phase 2 COVID-19 clinical studies within their hospitals using first-in-class drug ? apabetalone. Following Health Canada?s approval for the company?s COVID-19 clinical trials, it has been actively working with hospitals and ministries to commence COVID-19 trials globally. On October 12, 2021, the company received ethics committee approval for COVID-19 clinical trials in Western Canadian sites. Additionally, a Phase 3 COVID-19 trial in the US is anticipated to commence in coming months based on final protocol approval. Phase 2 Trial Overview? Canada/Brazil: study participants will be made up of patients hospitalized with confirmed COVID-19 cases. Participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care, compared to standard of care alone. The primary outcome measure of the study will be change in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. A total of 100 patients are expected to be enrolled at multiple sites in Canada and Brazil.